Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
Among adults with active lupus nephritis, obinutuzumab plus standard therapy was more efficacious than standard therapy alone in providing a complete renal response. (Funded by F. Hoffmann-La Roche; REGENCY ClinicalTrials.gov number, NCT04221477.).
Authors
- Jorge Ross Terrés
- Amit Saxena (ORCID: https://orcid.org/0000-0003-0098-1083)
- Ana Malvar (ORCID: https://orcid.org/0000-0003-1609-3857)
- Himanshi Sehgal
- Harini Raghu
- Fedra Irazoque Palazuelos
- Brad H. Rovin (ORCID: https://orcid.org/0000-0001-5639-0210)
- Elsa Martins
- Dámaris Álvarez (ORCID: https://orcid.org/0000-0003-1751-8386)
- Gustavo Aroca (ORCID: https://orcid.org/0000-0002-9222-3257)
- Iftekhar Hassan (ORCID: https://orcid.org/0000-0001-6993-9954)
- Thomas H. Schindler (ORCID: https://orcid.org/0000-0002-2141-7716)
- Richard Alan Furie (ORCID: https://orcid.org/0000-0001-6712-1585)
- Theodore A. Omachi (ORCID: https://orcid.org/0000-0001-9167-768X)
- William F. Pendergraft
- Alexander Lila
- Jay Garg
- Bongin Yoo
- Adolfina Elizabeth Zuta Santillán
- Claudio Sandoval (ORCID: https://orcid.org/0000-0002-5463-7731)
- Mittermayer B. Santiago
- James A. Tumlin
- Petra Kirchner
Institutions
- Roche (Switzerland) (CH)
- Universidade Federal da Bahia (BR)
- Northwell Health (US)
- Escola Bahiana de Medicina e Saúde Pública (BR)
- Universidad Privada San Juan Bautista (PE)
- Roche (Canada) (CA)
- University of the Coast (CO)
- Association of Rheumatologists of Russia (RU)
- Universidad Simón Bolívar (CO)
- Clinical Research Consortium (US)
- The Ohio State University (US)
- New York University (US)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-02-07
- DOI
- https://doi.org/10.1056/nejmoa2410965
- Citations
- 144
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 240.20
Funders
- F. Hoffmann-La Roche